|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2007-11-8
|
|
pubmed:abstractText |
The purine analogs pentostatin and cladribine have revolutionized the treatment of hairy cell leukemia (HCL) with overall responses in greater than 85% of patients and a median progression-free survival of up to 15 years. They continue to be effective at second- and even third-line therapy; however, alternative treatments are needed for patients who are or have become refractory to these agents or whose remissions are shorter with each course of therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2007 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
110
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2240-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17886250-Adult,
pubmed-meshheading:17886250-Aged,
pubmed-meshheading:17886250-Antibodies, Monoclonal,
pubmed-meshheading:17886250-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:17886250-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17886250-Cladribine,
pubmed-meshheading:17886250-Female,
pubmed-meshheading:17886250-Humans,
pubmed-meshheading:17886250-Leukemia, Hairy Cell,
pubmed-meshheading:17886250-Male,
pubmed-meshheading:17886250-Middle Aged,
pubmed-meshheading:17886250-Pentostatin,
pubmed-meshheading:17886250-Recurrence
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
|
|
pubmed:affiliation |
Section of Haemato-Oncology, Royal Marsden Hospital/Institute of Cancer Research, Sutton, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
